(MT Newswires) -- Novo Nordisk A/S (NVO) will sell its Wegovy obesity drug in larger European markets in 2023 after resolving production problems that has held back sales of the weekly injection in the US. Chief Executive Officer Lars Fruergaard Jorgensen speaks on "Bloomberg Markets."
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
927.3 DKK | +1.13% | -0.16% | +32.83% |
31/05 | Zealand Pharma Secures EU Panel Backing for Severe Hypoglycemia Treatment | MT |
30/05 | Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.83% | 60TCr | |
+40.73% | 74TCr | |
-6.30% | 35TCr | |
+15.15% | 32TCr | |
+4.05% | 28TCr | |
+15.00% | 24TCr | |
-5.52% | 21TCr | |
+6.17% | 16TCr | |
-0.45% | 16TCr | |
-.--% | 12TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Sees Strong Demand for Obesity Drug